Parabilis Medicines, Inc.: 5%+ holders

As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Parabilis Medicines, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 23.8%. 3 filings are on record since June 18, 2026 (Schedule 13D, June 18, 2026).

ARCH Venture Fund XII, L.P. also filed stake reports on 5 other companies ↓

Sell to companies like Parabilis Medicines, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: ARCH Venture Fund XII, L.P. · Sole voting: 0 · Shared voting: 6,412,780 · Sole dispositive: 0 · Shared dispositive: 6,412,780 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-06 · Reporting person: Fmr LLC · Sole voting: 10,292,735 · Shared voting: 0 · Sole dispositive: 10,292,735 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-06
• Filing 2026-06-18 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 28,933,371 · Sole dispositive: 0 · Shared dispositive: 28,933,371 · SCHEDULE 13D, 2026-06-18

Parabilis Medicines, Inc. has 3 Schedule 13D or 13G filings on record since 2026-06-18. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Parabilis Medicines, Inc. and the warning signs.

See Parabilis Medicines, Inc.'s free Snapshot Watch Parabilis Medicines, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Parabilis Medicines, Inc. and the records around it.

Parabilis Medicines, Inc. elsewhere on the record

• Leadership changes Sep 2026
• Who owns it

Companies that share a holder

• ARCH Venture Fund XII, L.P. also filed stake reports on 5 other companies: City Therapeutics, Inc. (Oct 2026), Seaport Therapeutics, Inc. (May 2026), Neumora Therapeutics, Inc. (Apr 2026)
• RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
• FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)

Want the whole picture on Parabilis Medicines, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Parabilis Medicines, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Parabilis Medicines, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Parabilis Medicines, Inc. by CUSIP 698955101 and gives its principal executive office as 30 Acorn Park Drive, Cambridge, MA 02140 (SCHEDULE 13G, 2026-08-14).

What the percentages are based on

The information required by Item 4(b) is incorporated by reference to Row 11 of the cover pages hereto. The percentages set forth on the cover sheet for each Reporting Person are based upon 121,952,030 shares of Common Stock outstanding as of August 10, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026.ARCH Venture Fund XII, L.P., SCHEDULE 13G, 2026-08-14

Source of funds (Item 3)

Prior to the Issuer's initial public offering (the "IPO"), (i) the Fund purchased 642,250 shares of Series E preferred stock of the Issuer and 9,445,363 shares of Series F preferred stock of the Issuer; and (ii) the Nexus Fund III purchased 160,562 shares of Series E preferred stock of the Issuer and 1,666,829 shares of Series F preferred stock of the Issuer. The aggregate purchase price of the foregoing securities was $73,499,989.RA Capital Management, L.P., SCHEDULE 13D, 2026-06-18

Purpose of Transaction (Item 4)

RA Capital Management, L.P.

The Reporting Persons acquired the voting common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving from development-stage or commercial programs of the Issuer, or dispose of Issuer securities they beneficially own, on the open market or in private transactions or otherwise (including by means of 10b5-1 programs), consistent with their investment purposes and in amounts, on such terms and at such times as to be determined by the Reporting Persons based upon a number of factors, including, without limitation, their ongoing assessment of the Issuer's business prospects, the availability of Issuer securities at prices that would make the purchase or sale of such securities desirable, prevailing market conditions, the availability of other investment opportunities, and/or other considerations. In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including stockholders of the Issuer, officers of the Issuer, members of the board of directors of the Issuer, and/or or other third parties, to discuss matters regarding the Issuer, including but not …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-18; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Parabilis Medicines, Inc.

Who owns Parabilis Medicines, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Parabilis Medicines, Inc.: RA Capital Management, L.P. (23.8%, Schedule 13D, filed 2026-06-18), Fmr LLC (8.5%, Schedule 13G, filed 2026-08-06) and ARCH Venture Fund XII, L.P. (5.3%, Schedule 13G, filed 2026-08-14).

Who are the largest shareholders of Parabilis Medicines, Inc.?

By the share each holder's latest filing reports, the largest holders of Parabilis Medicines, Inc. on this page are RA Capital Management, L.P. (23.8%), Fmr LLC (8.5%) and ARCH Venture Fund XII, L.P. (5.3%).

When did RA Capital Management, L.P. buy into Parabilis Medicines, Inc.?

The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13D, filed 2026-06-18, reporting 23.8%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Parabilis Medicines, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Parabilis Medicines, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Parabilis Medicines, Inc. is mentioned again
• Find former Parabilis Medicines, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes